16 recruiting, 12 active not recruiting, 9 unknown, 8 completed. 27 Phase 2, 8 Phase 1, 3 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Melanoma Stage III: new trials by email Literature Review of Melanoma Stage III trials Research Report on Melanoma Stage III
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma PRTX007, Pembrolizumab - Melanoma Stage III | Phase 2 | Recruiting | Primmune Therapeutics, Inc. | 48 | 2026-07-01 | 2026-10-23 |
| To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate - Melanoma Stage III, Melanoma Stage IV | Phase 1 | Recruiting | Inge Marie Svane | 10 | 2025-04-01 | 2025-08-24 |
| Clinical and Ultrasound Incidence of Rheumatologic Immune Related Adverse Events in Stage IIB-IV Melanoma Patients Joint ultrasonography, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire - Core 30 version 3.0 - Melanoma, Stage II, Melanoma Stage III | Not yet recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 100 | 2025-02-01 | 2025-01-17 | |
| Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma Pembrolizumab, Cyclophosphamide - Melanoma, Melanoma Stage III | Phase 2 | Recruiting | University of California, Irvine | 14 | 2024-12-23 | 2026-03-10 |
| Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients L19IL2, L19TNF, L19IL2/L19TNF - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | Philogen S.p.A. | 162 | 2024-07-12 | 2026-09-02 |
| Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients FYB206, Keytruda - Melanoma, Stage II, Melanoma Stage III | Phase 1 | Completed | Formycon AG | 96 | 2024-07-01 | 2026-10-20 |
| Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma Nivolumab, Nivolumab + Relatlimab, Ipilimumab - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 90 | 2024-05-17 | 2026-04-01 |
| Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies MB-CART19.1, MB-CART20.1, MB-CART2019.1 - Melanoma Stage III, B-cell Non Hodgkin Lymphoma | Not applicable | Recruiting | Miltenyi Biomedicine GmbH | 40 | 2024-05-05 | 2026-10-09 |
| Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients 18F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography - Melanoma, Melanoma Stage III | Recruiting | University of Wisconsin, Madison | 24 | 2024-01-30 | 2026-01-20 | |
| A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors KB707, Opdualag, KEYTRUDA ®( Pembrolizumab) - Cancer, Melanoma Stage III | Phase 1 / Phase 2 | Recruiting | Krystal Biotech, Inc. | 240 | 2023-10-31 | 2025-05-18 |
| MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma [203Pb]VMT01, [212Pb]VMT01, Nivolumab - Recurrent Melanoma (Skin), Metastatic Melanoma | Phase 1 / Phase 2 | Recruiting | Perspective Therapeutics | 300 | 2023-06-01 | 2026-10-13 |
| The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma Toripalimab combined with Temozolomide - Melanoma Stage III | Phase 2 | Unknown | Yong Chen | 20 | 2023-05-01 | 2023-04-25 |
| A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma BCD-217, anti-PD1, Excision of the primary lesion - Melanoma Stage III, Melanoma (Skin) | Phase 3 | Active not recruiting | Biocad | 411 | 2023-04-05 | 2025-07-08 |
| Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial nivolumab - Melanoma Stage IV, Melanoma Stage III | Not applicable | Recruiting | Erasmus Medical Center | 80 | 2023-02-01 | 2025-02-28 |
| A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma Regorafenib 40 MG Oral Tablet, Triplet therapy - Melanoma Stage III, Melanoma Stage IV | Phase 2 | Active not recruiting | Universitair Ziekenhuis Brussel | 48 | 2022-10-03 | 2026-09-30 |
| Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG MSOT - Melanoma, Stage I, Melanoma, Stage II | Phase 4 | Unknown | University Medical Center Groningen | 10 | 2022-09-01 | 2022-07-20 |
| FMT to Convert Response to Immunotherapy Fecal microbiota transplantation - Melanoma Stage III, Melanoma Stage IV | Phase 1 / Phase 2 | Recruiting | The Netherlands Cancer Institute | 24 | 2022-08-31 | 2025-03-10 |
| A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma BCD-217, BCD-100, Placebo - Melanoma, Melanoma (Skin) | Phase 3 | Active not recruiting | Biocad | 270 | 2022-08-02 | 2025-02-27 |
| Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT) Melanoma Stage III | Unknown | Hospital Universitario Virgen Macarena | 68 | 2022-07-01 | 2022-07-06 | |
| Versatile Ampification Single-Molecule Detection in Liquid Biopsy Blood sampling in addition to the blood normally required for their clinical management, Blood plasma and circulating tumor DNA (ctDNA) - Liquid Biopsy, Melanoma (Skin) | Recruiting | Regina Elena Cancer Institute | 20 | 2022-04-27 | 2024-11-27 |
Showing 20 of 49. Sign in to see all of them.
Melanoma (49) · Skin Neoplasms (3) · Diabetes Mellitus, Insulin-Dependent, 12 (2) · Drug-Related Side Effects and Adverse Reactions (2) · Adenoviridae Infections (1) · Carcinoma, Non-Small-Cell Lung (1) · Colitis (1) · Kidney Neoplasms (1) · Leukemia, Lymphocytic, Chronic, B-Cell (1) · Lymphatic Metastasis (1) · Lymphoma, B-Cell (1) · Neoplasms (1) · Ovarian Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Uveal Melanoma (1)
Neoplasms by Histologic Type (49) · Neoplasms by Site (49) · Neoplasms, Germ Cell and Embryonal (49) · Neoplasms, Nerve Tissue (49) · Neuroectodermal Tumors (49) · Neuroendocrine Tumors (49) · Nevi and Melanomas (49) · Skin Diseases (49) · Skin and Connective Tissue Diseases (49) · Neoplasms (48) · Skin Neoplasms (46) · Chemically-Induced Disorders (2) · Pathologic Processes (2) · Pathological Conditions, Signs and Symptoms (2) · Adnexal Diseases (1)
Nivolumab (12) · Ipilimumab (7) · pembrolizumab (7) · binimetinib (4) · encorafenib (3) · Blood Specimen Collection (2) · Cyclophosphamide (2) · Denosumab (2) · Opdualag (2) · aldesleukin (2) · CD4-CD8 Ratio (1) · Circulating Tumor DNA (1) · Cisplatin (1) · Dacarbazine (1) · Dried Blood Spot Testing (1)
H. Lee Moffitt Cancer Center and Research Institute (3) · Biocad (2) · MelanomaPRO, Russia (2) · The Netherlands Cancer Institute (2) · Abramson Cancer Center at Penn Medicine (1) · BioNTech SE (1) · Dana-Farber Cancer Institute (1) · Diwakar Davar (1) · Erasmus Medical Center (1) · Evaxion Biotech A/S (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Formycon AG (1) · Grupo Español Multidisciplinar de Melanoma (1) · Hospital Universitario Virgen Macarena (1) · Inge Marie Svane (1)
United States (20) · Australia (6) · Russia (6) · Germany (5) · Italy (5) · Netherlands (5) · United Kingdom (5) · Spain (4) · Poland (3) · Austria (2) · Belarus (2) · Romania (2) · Belgium (1) · Bosnia and Herzegovina (1) · Bulgaria (1)
Ahmad Tarhini, MD, PhD (2) · Cecilie D Vestergaard, M.D. (1) · Charlotte Proby, MBBS,FRCP (1) · Danielle Bello (1) · David Chien, MD (1) · Diwakar Davar, MD (1) · Dr Bavanthi Balakrishnar (1) · Elizabeth I Buchbinder, MD (1) · Georgina V Long (1) · Inge Marie Svane, Prof., M.D. (1) · John Haanen, Prof (1)
PMID 36648215, PMID 35073733, PMID 35927710, PMID 36585700, PMID 38783238, PMID 39469641, PMID 40715648, PMID 41313559, PMID 41420791
2023 (2), R44CA217591 (1)